secwatch.observer — SEC 8-K summary
======================================

Issuer:     PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK:        0001401667
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001437749-24-033929
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Puma Biotech Q3 net income $20.3M vs $5.8M YoY; raises FY 2024 guidance
-----------------------------------------------------------------------

- Product revenue $56.1M (+8.7% YoY); total revenue $80.5M including $24.4M royalty revenue.
- GAAP EPS $0.41 diluted; adjusted non-GAAP EPS $0.45 diluted.
- FY 2024 net product revenue guidance raised to $187-190M (from $183-190M); net income raised to $15-17M.
- Cash & securities $97M at Sept 30; operating cash flow $11M in Q3.
- Phase II alisertib trials in SCLC and breast cancer on track; interim data expected in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401667/000143774924033929/0001437749-24-033929-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401667/000143774924033929/pbyi20241106_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-033929

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer